{
    "root": "302614d9-cc10-737a-e063-6294a90a41c3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "MUTAMYCIN",
    "value": "20250312",
    "ingredients": [
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "MITOMYCIN",
            "code": "50SG953SK6",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25357"
        }
    ],
    "indications": {
        "text": "mutamycin \u00ae ( mitomycin ) injection recommended single-agent , primary therapy . shown useful therapy disseminated adenocarcinoma stomach pancreas proven combinations approved chemotherapeutic agents palliative treatment modalities failed . mitomycin recommended replace appropriate surgery and/or radiotherapy .",
        "doid_entities": [
            {
                "text": "disseminated adenocarcinoma (DOID:4912)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4912"
            },
            {
                "text": "adenocarcinoma (DOID:299)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_299"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "parenteral products inspected visually particulate matter discoloration prior whenever solution container permit . mitomycin given intravenously , using care avoid extravasation compound . extravasation occurs , cellulitis , ulceration , slough may result . vial contains either mitomycin 5 mg mannitol 10 mg , mitomycin , 20 mg mannitol 40 mg mitomycin 40 mg mannitol 80 mg. administer , add sterile water injection , 10 ml , 40 ml 80 ml respectively . shake dissolve . product dissolve immediately , allow stand room temperature solution obtained . full hematological recovery ( guide adjustment ) previous chemotherapy , following schedule may used 6 8 week intervals : 20 mg/m 2 intravenously single dose via functioning intravenous catheter . cumulative myelosuppression , patients fully reevaluated course mitomycin , dose reduced patient experienced toxicities . doses greater 20 mg/m 2 shown effective , toxic lower doses . following schedule suggested guide adjustment : nadir prior dose leukocytes/mm 3 platelets/mm 3 percentage prior dose given > 4000 > 100,000 100 % 3000\u20133999 75,000\u201399,999 100 % 2000\u20132999 25,000\u201374,999 70 % < 2000 < 25,000 50 % repeat given leukocyte count returned 4000/mm 3 platelet count 100,000/mm 3. mitomycin used combination myelosuppressive agents , doses adjusted accordingly . disease continues progress two courses mitomycin , stopped since chances response minimal .",
        "doid_entities": [
            {
                "text": "cellulitis (DOID:3488)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3488"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "mutamycin \u00ae ( mitomycin ) injection usp ndc 69448-001-05\u2014each amber vial contains 5 mg mitomycin , individually packed single carton . ndc 69448-002-11\u2014each amber vial contains 20 mg mitomycin , individually packed single carton . ndc 69448-003-38\u2014each amber vial contains 40 mg mitomycin , individually packed single carton . storage : store dry powder 25\u00b0c , excursion permitted 15\u00b0c 30\u00b0c , protected light . avoid excessive heat , 40 \u00b0c ( 104\u00b0 f ) . protect reconstituted solution light . store solution refrigeration 2\u00b0 8 \u00b0c ( 36\u00b0 46\u00b0f ) , discard 14 days . unrefrigerated , discard 7 days .",
    "adverseReactions": "mitomycin contraindicated patients demonstrated hypersensitive idiosyncratic reaction past . mitomycin contraindicated patients thrombocytopenia , coagulation disorder , increase bleeding tendency due causes .",
    "indications_original": "MUTAMYCIN\n       \n \n  \u00ae (Mitomycin) for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy.",
    "contraindications_original": "Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.\n                  Mitomycin should be given intravenously only, using care to avoid extravasation of the compound. If extravasation occurs, cellulitis, ulceration, and slough may result.\n                  Each vial contains either mitomycin 5 mg and mannitol 10 mg, mitomycin, 20 mg and mannitol 40 mg or mitomycin 40 mg and mannitol 80 mg. To\nadminister, add Sterile Water for Injection, 10 mL, 40 mL or 80 mL respectively. Shake to dissolve. If product does not dissolve immediately, allow to stand at room temperature until solution is obtained.\n                  After full hematological recovery (see guide to dosage adjustment) from any previous chemotherapy, the following dosage schedule may be used at\n6 to 8 week intervals:\n                  20 mg/m\n       \n \n  \n       \n \n  2 intravenously as a single dose via a functioning intravenous catheter.\n      \n\n \n      \n\n \n                  Because of cumulative myelosuppression, patients should be fully reevaluated after each course of mitomycin, and the dose reduced if the patient has experienced any toxicities. Doses greater than 20 mg/m\n       \n \n  \n       \n \n  2 have not been shown to be more effective, and are more toxic than lower doses.\n      \n\n \n      \n\n \n                  The following schedule is suggested as a guide to dosage adjustment:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              Nadir After Prior Dose\n                           \n                        \n                        \n                           \n                              Leukocytes/mm\n           \n     \n      \n           \n     \n      3\n                              \n                           \n                           \n                              Platelets/mm\n           \n     \n      \n           \n     \n      3\n                              \n                           \n                           \n                              Percentage of \n           \n     \n      \n           \n     \n      Prior Dose \n           \n     \n      \n           \n     \n      To Be Given\n          \n    \n     \n          \n    \n     \n                           \n                        \n                        \n                           >4000 \n                           >100,000\n                           100%\n                        \n                        \n                           3000\u20133999\n                           75,000\u201399,999\n                           100%\n                        \n                        \n                           2000\u20132999\n                           25,000\u201374,999\n                           70%\n                        \n                        \n                           <2000\n                           <25,000\n                           50%\n                        \n                     \n                  \n                  No repeat dosage should be given until leukocyte count has returned to 4000/mm\n       \n \n  \n       \n \n  3 and a platelet count to 100,000/mm\n       \n \n  \n       \n \n  3. When mitomycin is used in combination with other myelosuppressive agents, the doses should be adjusted accordingly. If the disease continues to progress after two courses of mitomycin, the drug should be stopped since chances of response are minimal.",
    "warningsAndPrecautions_original": "MUTAMYCIN\n       \n \n  \u00ae (Mitomycin) for Injection USP\n      \n\n \n                  NDC 69448-001-05\u2014Each amber vial contains 5 mg mitomycin, individually packed in single carton.\n                  NDC 69448-002-11\u2014Each amber vial contains 20 mg mitomycin, individually packed in single carton.\n                  NDC 69448-003-38\u2014Each amber vial contains 40 mg mitomycin, individually packed in single carton.\n                  \n                     Storage: Store dry powder at 25\u00b0C, excursion permitted between 15\u00b0C and 30\u00b0C, protected from light. Avoid excessive heat, over 40 \u00b0C (104\u00b0 F). Protect reconstituted solution from light. Store solution under refrigeration 2\u00b0 to 8 \u00b0C (36\u00b0 to 46\u00b0F), discard after 14 days. If unrefrigerated, discard after\n7 days.",
    "adverseReactions_original": "Mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past.\n                  Mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes.",
    "drug": [
        {
            "name": "MUTAMYCIN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        }
    ]
}